Archive | Press Releases

RSS feed for this section

Daxor Corporation to Present at The MicroCap Conference on October 2, 2018

NEW YORK – September 25, 2018 – Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement, today announced that Michael Feldschuh, chief executive officer of Daxor, will be a featured presenter at The MicroCap Conference on Tuesday,  October 2, 2018 at 4:30 PM ET. The conference is […]

New Independent Data Further Demonstrates Clinical Utility of Daxor Corporation’s Blood Volume Analyzer (BVA-100) Over Surrogate Measurements

NEW YORK, Sept. 17, 2018 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced the presentation of two Mayo Clinic studies showing that direct blood volume analysis provides doctors with important information to inform treatment, and does so at an advantage over […]

Daxor Corporation to Exhibit at the 22nd Annual Scientific Meeting of the Heart Failure Society of America

NEW YORK, Sept. 12, 2018 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today announces it will be attending the 22nd Annual Scientific Meeting of the Heart Failure Society of America (HFSA) at the Gaylord Opryland Hotel and Convention Center in Nashville, TN from […]

Daxor Corporation Announces a 23 Percent Rise in BVA-100 Kit Sales in the Area of Cardiology and Filing of Form N-CSR for June 30, 2018

NEW YORK – August 24, 2018 – Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations filed a Form N-CSR disclosing its schedule of portfolio holdings as of June 30, 2018. In reporting its mid-year results, Daxor Corporation has seen important developments in 2018 including a 23 percent rise […]

Newly Published Data Show Daxor Corporation’s BVA-100 Is Superior To Formula-Based Estimates of Blood Volume In Assessing Patients With Heart Failure

NEW YORK – August 20, 2018 – Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the publication of an investigator-initiated study from Duke University and The Mayo Clinic demonstrating that despite the widespread use of formula-derived estimates of plasma volume in heart failure patients, […]

Daxor Corporation Appoints Kathryn A. Kornafel Vice President of Marketing and Commercial Development

NEW YORK , June 12, 2018 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the appointment of Kathryn A. Kornafel as vice president of Marketing and Commercial Development. “Kathryn’s extensive marketing experience within the diagnostic, cardiovascular and point-of-care arenas position her to […]

Daxor Corporation Initiates Study with Virginia Commonwealth University to Measure Improvement of Survival Rates Following Burn Surgery As A Result of Optimized Blood Volume Assessment

NEW YORK – June 4, 2018 – Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the initiation of an investigator-initiated trial at Virginia Commonwealth University Medical Center that will incorporate the company’s patented BVA-100 diagnostic to assess blood volume loss during burn surgery. “Intravascular […]

DAXOR CORPORATION RETAINS CORE IR AS INVESTOR RELATIONS FIRM OF RECORD

NEW YORK, May 29, 2018 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces it has retained CORE IR as its Investor Relations firm of record. Core IR will provide comprehensive investor relations and shareholder communications services and assist the company in expanding […]

DAXOR CORPORATION TO PRESENT AT THE LD MICRO 8TH ANNUAL INVITATIONAL ON JUNE 4, 2018

NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement, announced that Michael Feldschuh, Chief Executive Officer of Daxor, will be a featured presenter at the LD Micro Invitational Conference on Monday June 4, 2018 at 4:30 PM Pacific Time. The […]

A New Study Published in The Annals of Thoracic Surgery: Daxor’s BVA-100 Device Reveals Unexpected Blood Loss of 38% in Cardiac Surgical Patients Not Detected by Common Test in Use

New York, NY, April 19, 2018 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announces the publication of new research utilizing the BVA-100 blood volume analyzer that highlights significant, often unrecognized blood loss in cardiac surgery. The paper entitled “Measurement of Blood Loss in Cardiac Surgery: Still […]